Evommune, Inc.: updates and filings

EVMNNYSEHealthcare · Pharmaceutical Preparations

Price

$7.04

November 20, 2026Market cap $291M

What Ploutos Investor adds for Evommune

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 75 daysAround Feb 5, 2027 · for Q4 2026

last Nov 12, 2026next Feb 5, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 5, 2026 latest annualNov 12, 2026 latest quarterly
  • Nov 17, 2026Officer or director change
    Form8-K
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 12, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Nov 10, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Nov 5, 2026Regulation FD disclosure
    Form8-K
  • Nov 4, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosure, other material events
    Form8-K
  • Oct 1, 2026Regulation FD disclosure
    Form8-K
  • Sep 23, 2026Regulation FD disclosure
    Form8-K
  • Sep 15, 2026Regulation FD disclosure
    Form8-K
  • Sep 9, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 6, 2026Results of operations
    Form8-K
  • Jul 30, 2026Regulation FD disclosure
    Form8-K
  • Jul 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jun 29, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jun 2, 2026Shareholder vote
    Form8-K
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 7, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Apr 24, 2026Filing
    FormEFFECT
  • Apr 22, 2026Correspondence with the SEC
    FormCORRESP
  • Apr 22, 2026Letter from the SEC
    FormUPLOAD

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 7, 2025.

The full analysis

What do Evommune's filings show?

The filings are where every one of Evommune's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.